Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0805 • ACR Convergence 2023
De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Navasuja Kumar¹, Mohammed Kabeto¹, Andrzej Galecki¹, Chiang-Hua Chang¹, Namrata Singh², Raymond Yung³, Una Makris⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²University of Washington, Bellevue, WA, ³Michigan Medicine, Ann Arbor, MI, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Biologic disease modifying anti-rheumatic drugs (bDMARDs) such as anti-tumor necrosis factors(anti-TNFs) improve clinical and radiographic outcomes in rheumatoid arthritis (RA). However, their use is…
Abstract Number: 0972 • ACR Convergence 2023
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Juan Marin¹, Enrique Mazenett¹, Mauricio Sarmiento¹, Rosalbina Perez¹, Claudia Morales¹, Jorge Dominguez¹, Juan Salazar² and Juan-Manuel Anaya³, ¹Coosalud, EPS, Cartagena, Colombia, ²Universidad Nacional, Medellin, Colombia, ³Coosalud, EPS, Bogotá, Colombia
Background/Purpose: An increase in the incidence of autoimmune diseases after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to…
Abstract Number: 1008 • ACR Convergence 2023
Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use
Emilie Pianarosa¹, Pamela Roach¹, Patrick McLane², Meghan Elliott¹, Brian Holroyd³, Shanon McQuitty⁴, Steven Katz³, Nazret Russon², Katie Lin¹, Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Emergency departments (ED) become a location for non-urgent care when ambulatory care systems are not sufficient. We aim to describe contributing factors to the…
Abstract Number: 1202 • ACR Convergence 2023
Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals
Jennifer Barton¹, Danielle ZuZero², Diego Molina Ochoa³, Rachel Matsumoto⁴ and Edward Yelin⁵, ¹VA Portland Health Care System/OHSU, Portland, OR, ²National University of Natural Medicine, Portland, OR, ³University of Maryland School of Medicine, Baltimore, MD, ⁴VA Portland Health Care System, Portland, OR, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Goal concordance between patients with chronic disease and their clinicians is linked to improved outcomes, however, less is known about goal concordance and goal…
Abstract Number: 1275 • ACR Convergence 2023
Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study
Alexandra Legge¹ and Diane Lacaille², ¹Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Studies have demonstrated a link between frailty and chronic inflammation, raising the question of whether chronic inflammatory diseases like rheumatoid arthritis (RA) may be…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 1307 • ACR Convergence 2023
Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
Clementina López Medina¹, Jerusalem Calvo², Lucia Otero-Valera³, Alejandro Escudero Contreras², Rafaela Ortega Castro⁴, Lourdes Ladehesa Pineda⁵, Cristina Campos⁶, Pilar Bernabeu-Gonzálvez⁷, Cristina Bohorquez⁸, Alicia Garcia Dorta⁹, Dolores Ruiz-Montesinos¹⁰, Manuel Enrique Pombo Suarez¹¹, Inmaculada Ros¹², Fernando Alonso³ and Isabel Castrejon¹³, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ⁶Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁷General University Hospital Dr. Balmis, Alicante, Spain, ⁸Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ⁹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities, compared to the general population. The presence of such comorbidities has been directly…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 1723 • ACR Convergence 2023
3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity
Brendan Allen¹, Sabrina Fechtner², Meagan Chriswell³, Widian Jubair¹, M. Aaron Vrolijk¹, V. Michael Holers⁴ and kristine Kuhn¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz SOM, Denver, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
Abstract Number: 1741 • ACR Convergence 2023
The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis
Sara Turcinov¹, Charlotte de Vries², Ravi Kumar Sharma², Christina Gerstner², Bruno Raposo², Anatoly Dubnovitsky², William Kwok³, Karine Chemin², Vivianne Malmström⁴ and Aase Hensvold⁵, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
Abstract Number: 1757 • ACR Convergence 2023
Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity
Michał Jakubaszek, Maria Maślińska and Brygida Kwiatkowska, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland
Background/Purpose: Usefulness of quantitative assessment of synovial vascularity in ultrasound (US) imaging in patients with active RA and PsA (peripheral arthritis). Additionally the assessment of…
Abstract Number: 1773 • ACR Convergence 2023
Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity
Eunice Choi¹, Camilla R. L. Machado², David Boyle¹, Wei Wang¹ and Gary Firestein², ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: Mechanisms responsible for the distribution and severity of joint involvement in RA are not known. To explore whether site-specific FLS biology might contribute to…
Abstract Number: 1895 • ACR Convergence 2023
Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Pritee Shrestha¹, Peter Larsen¹ and Pablo Weilg Espejo², ¹Mercy One North Iowa Medical Center, Mason City, IA, ²Boston Medical Center, Chelsea, MA
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].